These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35080624)

  • 1. Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die.
    Lim VG; He H; Lachlan T; Ng GA; Kyrou I; Randeva HS; Osman F
    Europace; 2022 Jul; 24(7):1052-1057. PubMed ID: 35080624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
    Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
    Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system.
    Azzam O; Matthews VB; Schlaich MP
    Curr Opin Nephrol Hypertens; 2022 Mar; 31(2):135-141. PubMed ID: 35086983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
    Cruz JE; Ahuja T; Bridgeman MB
    Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.
    Sano M
    J Cardiol; 2018 May; 71(5):471-476. PubMed ID: 29415819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
    Bailey CJ; Day C; Bellary S
    Curr Diab Rep; 2022 Jan; 22(1):39-52. PubMed ID: 35113333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models.
    Andreadou I; Bell RM; Bøtker HE; Zuurbier CJ
    Biochim Biophys Acta Mol Basis Dis; 2020 Jul; 1866(7):165770. PubMed ID: 32194159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes.
    Čertíková Chábová V; Zakiyanov O
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is there a paradigm shift in preventing diabetic heart failure? A review of SGLT2 inhibitors.
    Khakde S; Jawaid H; Yasmin F; Binte Ali M; Rehman A
    Minerva Endocrinol (Torino); 2022 Sep; 47(3):344-357. PubMed ID: 33331740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.
    Packer M
    Diabetes Obes Metab; 2018 Jun; 20(6):1361-1366. PubMed ID: 29359851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.
    Herat LY; Matthews J; Azzam O; Schlaich MP; Matthews VB
    Curr Hypertens Rep; 2022 Mar; 24(3):67-74. PubMed ID: 35235172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 Inhibitors in Type 2 Diabetes Mellitus.
    Ferrannini G; Savarese G; Cosentino F
    Heart Fail Clin; 2022 Oct; 18(4):551-559. PubMed ID: 36216485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatment.
    D'Onofrio N; Sardu C; Trotta MC; Scisciola L; Turriziani F; Ferraraccio F; Panarese I; Petrella L; Fanelli M; Modugno P; Massetti M; Marfella LV; Sasso FC; Rizzo MR; Barbieri M; Furbatto F; Minicucci F; Mauro C; Federici M; Balestrieri ML; Paolisso G; Marfella R
    Mol Metab; 2021 Dec; 54():101337. PubMed ID: 34500107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
    Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming.
    Gao YM; Feng ST; Wen Y; Tang TT; Wang B; Liu BC
    EBioMedicine; 2022 Sep; 83():104215. PubMed ID: 35973390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure.
    Scheen AJ
    Curr Cardiol Rep; 2019 Jun; 21(8):70. PubMed ID: 31227915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.